Alto Neuroscience Inc.’s filing revealed that its CHIEF MEDICAL OFFICER Savitz Adam acquired Company’s shares for reported $38748.0 on Jul 10 ’24. In the deal valued at $13.22 per share,2,931 shares were bought. As a result of this transaction, Savitz Adam now holds 39,851 shares worth roughly $0.36 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Savitz Adam bought 12,069 shares, generating $152,085 in total proceeds. Upon buying the shares at $12.60, the CHIEF MEDICAL OFFICER now owns 36,920 shares.
Before that, Smith Nicholas Conrad bought 6,150 shares. Alto Neuroscience Inc. shares valued at $100,628 were divested by the CHIEF FINANCIAL OFFICER at a price of $16.36 per share. As a result of the transaction, Smith Nicholas Conrad now holds 26,866 shares, worth roughly $0.24 million.
William Blair initiated its Alto Neuroscience Inc. [ANRO] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. Stifel began covering ANRO with “Buy” recommendation on February 27, 2024. Robert W. Baird started covering the stock on February 27, 2024. It rated ANRO as “an Outperform”.
Price Performance Review of ANRO
On Friday, Alto Neuroscience Inc. [NYSE:ANRO] saw its stock fall -7.14% to $9.11. Over the last five days, the stock has lost -36.56%. Alto Neuroscience Inc. shares have fallen nearly -55.99% since the year began. A total of 0.5 million shares were traded, compared to the trading of 0.57 million shares in the previous session.
Levels Of Support And Resistance For ANRO Stock
The 24-hour chart illustrates a support level at 8.65, which if violated will result in even more drops to 8.19. On the upside, there is a resistance level at 9.70. A further resistance level may holdings at 10.30. The Relative Strength Index (RSI) on the 14-day chart is 28.36, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.86, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.24%. Stochastics%K at 3.62% indicates the stock is a buying.
The most recent change occurred on February 27, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
